FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...

Vevye will be included in key formularies of major plan sponsors, covering over 25 million Medicare Part D beneficiaries ...

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...

Pediatric cataract surgeries are more costly than adult procedures, with significant nonsurgical expenses like anesthesia and ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...

Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and ...

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...

A surge in AMN cases was observed in China post-zero-COVID policy, linked to SARS-CoV-2 Omicron infections. AMN is characterized by dark reddish macular lesions and retinal ischemia, with bilateral ...